维生素D补充对2型糖尿病合并维生素D缺乏者胰岛素敏感性和胰岛素分泌的影响:一项随机对照试验
该6个月随机双盲安慰剂对照试验纳入62例2型糖尿病合并维生素D缺乏(25-羟维生素D<50 nmol/L)的男性和女性,给予单次口服400,000 IU维生素D3或安慰剂,维生素D组4周后若血清25-羟维生素D<100 nmol/L则追加200,000 IU。结果显示大剂量维生素D3补充未改变胰岛素敏感性或胰岛素分泌。
要点
- 维生素D组6个月25-羟维生素D总暴露量曲线下面积为1,870±192 nmol/L每周,安慰剂组为1,090±377 nmol/L每周(P<0.001)。
- 治疗后胰岛素敏感性、内源性葡萄糖生成和血糖控制组间及组内均无差异(P=0.52)。
- 第一相胰岛素分泌治疗后无显著变化(P=0.10)。
核心结论
- 对2型糖尿病合并维生素D缺乏患者补充大剂量维生素D3未改变胰岛素敏感性或胰岛素分泌。
- 这些发现不支持为此类患者使用治疗性维生素D3补充以改善血糖稳态。
研究设计与样本
- 6个月随机双盲安慰剂对照试验,纳入62例2型糖尿病合并维生素D缺乏(25-羟维生素D<50 nmol/L)的男性和女性。
- 参与者接受单次口服400,000 IU维生素D3或安慰剂,维生素D组4周后若血清25-羟维生素D<100 nmol/L则追加200,000 IU维生素D3。
- 主要终点为高胰岛素-正葡萄糖钳夹评估的总葡萄糖处置率(Rd)并评估内源性葡萄糖生成,以及静脉葡萄糖耐量试验评估的第一相胰岛素分泌。
主要发现
- 维生素D组平均±标准差基线血清25-羟维生素D为38.0±12.6 nmol/L,4周后升至96.9±18.3 nmol/L,3个月后为73.2±13.7 nmol/L,6个月后为53.7±9.2 nmol/L。
- 6个月期间25-羟维生素D总暴露量(曲线下面积)维生素D组为1,870±192 nmol/L每周,安慰剂组为1,090±377 nmol/L每周(P<0.001)。
- 治疗后胰岛素敏感性、内源性葡萄糖生成和血糖控制组间及组内均无差异(P=0.52)。
- 第一相胰岛素分泌治疗后无显著变化(P=0.10)。
临床怎么用
- 原文结论指出这些发现不支持为此类患者使用治疗性维生素D3补充以改善血糖稳态。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In observational studies, low vitamin D levels are associated with type 2 diabetes (T2D), impaired glucose metabolism, insulin sensitivity, and insulin secretion. We evaluated the efficacy of vitamin D supplementation on insulin sensitivity and insulin secretion in subjects with T2D and low vitamin D (25-hydroxyvitamin D [25(OH)D] <50 nmol/L). RESEARCH DESIGN AND METHODS: Sixty-two men and women with T2D and vitamin D deficiency participated in a 6-month randomized, double-blind, placebo-controlled trial. Participants received a single dose of 400,000 IU oral vitamin D3 or placebo, and the vitamin D group received an additional 200,000 IU D3 if serum 25(OH)D was <100 nmol/L after 4 weeks. Primary end points were total Rd by euglycemic clamp with assessment of endogenous glucose production and first-phase insulin secretion by intravenous glucose tolerance test. RESULTS: In the vitamin D group, the mean ± SD baseline serum 25(OH)D of 38.0 ± 12.6 nmol/L increased to 96.9 ± 18.3 nmol/L after 4 weeks, 73.2 ± 13.7 nmol/L after 3 months, and 53.7 ± 9.2 nmol/L after 6 months. The total exposure to 25(OH)D during 6 months (area under the curve) was 1,870 ± 192 and 1,090 ± 377 nmol/L per week in the vitamin D and placebo groups, respectively (P < 0.001). Insulin sensitivity, endogenous glucose production, and glycemic control did not differ between or within groups after treatment (P = 0.52). First-phase insulin secretion did not change significantly after treatment (P = 0.10). CONCLUSIONS: Replenishment with a large dose of vitamin D3 to patients with T2D and vitamin D deficiency did not change insulin sensitivity or insulin secretion. These findings do not support such use of therapeutic vitamin D3 supplementation to improve glucose homeostasis in patients with T2D.
引用
- Gulseth HL, Wium C, Angel K, et al. Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial. Diabetes Care. 2017. PMID: 28468770. doi:10.2337/dc16-2302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。